How to buy OpGen stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy OpGen stock

Own OpGen stock in just a few minutes.

OpGen, Inc is a diagnostics & research business based in the US. OpGen shares (OPGN) are listed on the NASDAQ and all prices are listed in US Dollars. OpGen employs 94 staff and has a trailing 12-month revenue of around USD$4.2 million.

How to buy shares in OpGen

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for OpGen. Find the stock by name or ticker symbol: OPGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until OpGen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of OpGen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of OpGen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

OpGen share price

Use our graph to track the performance of OPGN stocks over time.

OpGen shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$1.63 - USD$4.05
50-day moving average USD$2.6468
200-day moving average USD$2.2979
Wall St. target priceUSD$5.5
PE ratio 0.4601
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-26.103

Buy OpGen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy OpGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is OpGen under- or over-valued?

Valuing OpGen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OpGen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

OpGen's P/E ratio

OpGen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, OpGen shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

OpGen financials

Revenue TTM USD$4.2 million
Gross profit TTM USD$-9,598,770
Return on assets TTM -44.65%
Return on equity TTM -205.7%
Profit margin 0%
Book value $0.845
Market capitalisation USD$104.1 million

TTM: trailing 12 months

Shorting OpGen shares

There are currently 873,384 OpGen shares held short by investors – that's known as OpGen's "short interest". This figure is 47.7% up from 591,396 last month.

There are a few different ways that this level of interest in shorting OpGen shares can be evaluated.

OpGen's "short interest ratio" (SIR)

OpGen's "short interest ratio" (SIR) is the quantity of OpGen shares currently shorted divided by the average quantity of OpGen shares traded daily (recently around 29.1 million). OpGen's SIR currently stands at 0.03. In other words for every 100,000 OpGen shares traded daily on the market, roughly 30 shares are currently held short.

However OpGen's short interest can also be evaluated against the total number of OpGen shares, or, against the total number of tradable OpGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OpGen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 OpGen shares in existence, roughly 20 shares are currently held short) or 0.0226% of the tradable shares (for every 100,000 tradable OpGen shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against OpGen.

Find out more about how you can short OpGen stock.

OpGen share dividends

We're not expecting OpGen to pay a dividend over the next 12 months.

Have OpGen's shares ever split?

OpGen's shares were split on a 1:20 basis on 28 August 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OpGen shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for OpGen shares which in turn could have impacted OpGen's share price.

OpGen share price volatility

Over the last 12 months, OpGen's shares have ranged in value from as little as $1.63 up to $4.05. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OpGen's is -0.4468. This would suggest that OpGen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, OpGen has bucked the trend.

OpGen overview

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site